Clinical Research Directory
Browse clinical research sites, groups, and studies.
Montbretin Clinical Trial in Healthy Volunteers and Type 2 Diabetics
Sponsor: Robert Petrella
Summary
The goal of this clinical trial is to test the investigational product, Montbretin A (MbA) in either individuals with type 2 diabetes (T2D) or healthy participants. The main questions it aims to answer are: * Safety of MbA * Whether MbA has less side effects in comparison to other medications used to treat T2D Participants will: * Be given MbA at increasing amounts (10 mg to 300 mg) over a two-week treatment period, along with standardized meal; * Undergo testing, including blood draws, blood sugar checks, electrocardiogram (ECG) and questionnaires.
Official title: Phase 1 Dose Escalating Study for Montbretin a
Key Details
Gender
All
Age Range
19 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2023-12-01
Completion Date
2025-02
Last Updated
2024-10-15
Healthy Volunteers
Yes
Conditions
Interventions
Montbretin A
The investigational product is 95% pure montbretin A (MbA), a glycosylated acyl-flavonol isolated from the corms (bulbs) of the Crocosmia plant through hot water extraction. It is a potent and specific inhibitor of human pancreatic amylase (HPA).
Locations (1)
VCHRI Clinical Research Unit
Vancouver, British Columbia, Canada